Erming Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Erming Wang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhang
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA
3 shared publications - Michelle E. Ehrlich
Department of Neurology Icahn School of Medicine at Mount Sinai New York New York USA
3 shared publications Bin Zhang
Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY USA
2 shared publications- Dongming Cai
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA
2 shared publications - Minghui Wang
Icahn School of Medicine at Mount Sinai
2 shared publications - Sam Gandy
Department of Neurology Icahn School of Medicine at Mount Sinai New York New York USA
2 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 992
Molecular Networks and Key Regulators Underlying Resilience of the Human Brain to Aging and Dementia
Alzheimer’s disease (AD) is an aging-related neurodegenerative disease characterized by an initial memory impairment that progresses to a widespread cerebrocortical failure, culminating in death. Understanding the molecular mechanisms that protect brain function during aging may help reveal novel targets for the development of effective treatments for the memory and cognitive deficits associated with AD. In this study, we analyzed a gene expression dataset generated from the prefrontal cortices of individuals showing no neurological or cognitive abnormalities. The gene expression profiles were used to identify candidate protective genes. We then compared the expression patterns of these genes in aging with their expression patterns in AD, thereby enabling us to pinpoint the genes that potentially contribute to brain resilience that delays or prevents aging-related dementia. We selected seven genes that are potentially protective for aging and AD, and have known homologues in Caenorhabditis elegans (C. elegans). Among these genes, SRPK2, AAK1, EFR3A and MAPK10 were previously implicated in attenuating AD-related cognitive decline. Our experiments demonstrated that all seven genes prioritized by our resilience model significantly extended the lifespan of C. elegans. Given the important relationship between neuronal functional integrity and lifespan (i.e., lifespan vs. brain health span), this work suggests the predicted AD resilience genes could serve as important candidate targets for therapeutic intervention.
- 6 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 992
Open AccessMolecular Networks and Key Regulators Underlying Resilience of the Human Brain to Aging and Dementia
Alzheimer’s disease (AD) is an aging-related neurodegenerative disease characterized by an initial memory impairment that progresses to a widespread cerebrocortical failure, culminating in death. Understanding the molecular mechanisms that protect brain function during aging may help reveal novel targets for the development of effective treatments for the memory and cognitive deficits associated with AD. In this study, we analyzed a gene expression dataset generated from the prefrontal cortices of individuals showing no neurological or cognitive abnormalities. The gene expression profiles were used to identify candidate protective genes. We then compared the expression patterns of these genes in aging with their expression patterns in AD, thereby enabling us to pinpoint the genes that potentially contribute to brain resilience that delays or prevents aging-related dementia. We selected seven genes that are potentially protective for aging and AD, and have known homologues in Caenorhabditis elegans (C. elegans). Among these genes, SRPK2, AAK1, EFR3A and MAPK10 were previously implicated in attenuating AD-related cognitive decline. Our experiments demonstrated that all seven genes prioritized by our resilience model significantly extended the lifespan of C. elegans. Given the important relationship between neuronal functional integrity and lifespan (i.e., lifespan vs. brain health span), this work suggests the predicted AD resilience genes could serve as important candidate targets for therapeutic intervention.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e089178
DNA Methylation Drives Gene Networks Dysregulated in Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that inflicts the elderly worldwide. Recent studies revealed the association of abnormal methylomic alterations in AD. However, a systematic and comprehensive study is needed to investigate the effects of methylomic changes on the molecular networks underpinning AD, in particular, in brain regions most vulnerable to AD neuropathology.Method: We profiled genome‐wide methylomic variations in the parahippocampal gyrus across 201 postmortem control, mild cognitive impaired (MCI) and AD brains in the Mount Sinai Brain Bank (MSBB) cohort. We next investigated the influence of methylomic changes on both gene and protein co‐expression networks. We then integrated the methylomic, epigenomic (ATAC‐seq), transcriptomic and proteomic data to infer the regulatory relationships among DNA methylation, chromatin accessibility, transcription and translation. Finally, we validated our key findings using an independent cohort (Religious Orders Study/Memory and Aging Project (ROSMAP)).Result: We first demonstrated the existence of significant AD‐associated variation in methylomic sites genome‐wide, which were subsequently summarized into distinct differentially methylated regions (DMRs) that are critical in AD. We then quantified the effect of the DMRs on each gene and each protein as well as gene and protein co‐expression networks. We found that DNA methylation had profound influences on not only the AD‐associated gene/protein modules but also their key regulators in the networks. With the integration of the matched multiomics data, we unveiled that DNA methylation likely influenced gene/protein expression via epigenomic peak domains in AD. Further integration of the matched bulk tissue methylation and single nucleus multiomics data revealed cell‐type specific methylomic regulation of transcriptomics in AD.Conclusion: Our study is the most extensive genome‐wide investigation on the impact of methylation on AD pathology, and the first integrative survey on the complex interactions between methylation, chromatin accessibility, and multiscale transcriptomic and proteomics networks in AD.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e089178
Open AccessDNA Methylation Drives Gene Networks Dysregulated in Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that inflicts the elderly worldwide. Recent studies revealed the association of abnormal methylomic alterations in AD. However, a systematic and comprehensive study is needed to investigate the effects of methylomic changes on the molecular networks underpinning AD, in particular, in brain regions most vulnerable to AD neuropathology.Method: We profiled genome‐wide methylomic variations in the parahippocampal gyrus across 201 postmortem control, mild cognitive impaired (MCI) and AD brains in the Mount Sinai Brain Bank (MSBB) cohort. We next investigated the influence of methylomic changes on both gene and protein co‐expression networks. We then integrated the methylomic, epigenomic (ATAC‐seq), transcriptomic and proteomic data to infer the regulatory relationships among DNA methylation, chromatin accessibility, transcription and translation. Finally, we validated our key findings using an independent cohort (Religious Orders Study/Memory and Aging Project (ROSMAP)).Result: We first demonstrated the existence of significant AD‐associated variation in methylomic sites genome‐wide, which were subsequently summarized into distinct differentially methylated regions (DMRs) that are critical in AD. We then quantified the effect of the DMRs on each gene and each protein as well as gene and protein co‐expression networks. We found that DNA methylation had profound influences on not only the AD‐associated gene/protein modules but also their key regulators in the networks. With the integration of the matched multiomics data, we unveiled that DNA methylation likely influenced gene/protein expression via epigenomic peak domains in AD. Further integration of the matched bulk tissue methylation and single nucleus multiomics data revealed cell‐type specific methylomic regulation of transcriptomics in AD.Conclusion: Our study is the most extensive genome‐wide investigation on the impact of methylation on AD pathology, and the first integrative survey on the complex interactions between methylation, chromatin accessibility, and multiscale transcriptomic and proteomics networks in AD.
- Open Access
Proteomic profiling of intracranial atherosclerotic plaque in the human brain
Background Intracranial atherosclerotic disease (ICAD) is one of the major causes of ischemic stroke and associated with high risk of stroke recurrence. There are no reliable and specific fluid biomarkers for ICAD, and little is known about the proteomic profiling of ICAD. In this study we aimed to explore the feasibility of applying proteomics technology to profile intracranial atherosclerotic plaques extracted from postmortem human brain arteries. Methods Eighteen segments (5-10mm in length) of major arteries from 10 postmortem brains were collected from the Mount Sinai Neuropathology Brain Bank. Among these segments, 5 had no evidence of atherosclerotic disease, and 13 had wall thickening or visible plaques with various degree of stenosis. Proteins were extracted from the vessel segments, quantified, and digested into peptides. Subsequently, the peptides underwent tandem mass tag (TMT) labeling, pooling, and analysis using two-dimensional liquid chromatography-tandem mass spectrometry (LC/LC-MS/MS). Protein identification and quantification were performed using the JUMP software. Differentially expressed proteins (DEPs) were defined as proteins with p.adj < 0.05 and absolute log2 (fold change) > log2 (1.2). Results A total of 7,492 unique proteins were detected, and 6,726 quantifiable proteins were retained for further analysis. Among these, 265 DEPs, spanning on 252 unique gene, were found to be associated with ICAD by comparing the arterial segments with vs those without atherosclerotic disease. The top 4 most significant DEPs include LONP1, RPS19, MRPL12 and SNU13. Among the top 50 DEPs, FADD, AIFM1 and PGK1 were associated with atherosclerotic disease or cardiovascular events in previous studies. Moreover, the previously reported proteins associated with atherosclerosis such as APCS, MMP12, CTSD were elevated in arterial segments with atherosclerotic changes. Furthermore, the up-regulation of APOE and LPL, the ICAD GWAS risk genes, was shown to be associated with the plaque severity. Finally, gene set enrichment analysis revealed the DEP signature is enriched for biological pathways such as chromatin structure, plasma lipoprotein, nucleosome, and protein-DNA complex, peroxide catabolic and metabolic processes, critical in ICAD pathology. Conclusions Direct proteomic profiling of fresh-frozen intracranial artery samples by MS-based proteomic technology is a feasible approach to identify ICAD-associated proteins, which can be potential biomarker candidates for ICAD. Further plaque proteomic study in a larger sample size is warranted to uncover mechanistic insights into ICAD and discover novel biomarkers that may help to improve diagnosis and risk stratification in ICAD.
Open AccessProteomic profiling of intracranial atherosclerotic plaque in the human brain
Background Intracranial atherosclerotic disease (ICAD) is one of the major causes of ischemic stroke and associated with high risk of stroke recurrence. There are no reliable and specific fluid biomarkers for ICAD, and little is known about the proteomic profiling of ICAD. In this study we aimed to explore the feasibility of applying proteomics technology to profile intracranial atherosclerotic plaques extracted from postmortem human brain arteries. Methods Eighteen segments (5-10mm in length) of major arteries from 10 postmortem brains were collected from the Mount Sinai Neuropathology Brain Bank. Among these segments, 5 had no evidence of atherosclerotic disease, and 13 had wall thickening or visible plaques with various degree of stenosis. Proteins were extracted from the vessel segments, quantified, and digested into peptides. Subsequently, the peptides underwent tandem mass tag (TMT) labeling, pooling, and analysis using two-dimensional liquid chromatography-tandem mass spectrometry (LC/LC-MS/MS). Protein identification and quantification were performed using the JUMP software. Differentially expressed proteins (DEPs) were defined as proteins with p.adj < 0.05 and absolute log2 (fold change) > log2 (1.2). Results A total of 7,492 unique proteins were detected, and 6,726 quantifiable proteins were retained for further analysis. Among these, 265 DEPs, spanning on 252 unique gene, were found to be associated with ICAD by comparing the arterial segments with vs those without atherosclerotic disease. The top 4 most significant DEPs include LONP1, RPS19, MRPL12 and SNU13. Among the top 50 DEPs, FADD, AIFM1 and PGK1 were associated with atherosclerotic disease or cardiovascular events in previous studies. Moreover, the previously reported proteins associated with atherosclerosis such as APCS, MMP12, CTSD were elevated in arterial segments with atherosclerotic changes. Furthermore, the up-regulation of APOE and LPL, the ICAD GWAS risk genes, was shown to be associated with the plaque severity. Finally, gene set enrichment analysis revealed the DEP signature is enriched for biological pathways such as chromatin structure, plasma lipoprotein, nucleosome, and protein-DNA complex, peroxide catabolic and metabolic processes, critical in ICAD pathology. Conclusions Direct proteomic profiling of fresh-frozen intracranial artery samples by MS-based proteomic technology is a feasible approach to identify ICAD-associated proteins, which can be potential biomarker candidates for ICAD. Further plaque proteomic study in a larger sample size is warranted to uncover mechanistic insights into ICAD and discover novel biomarkers that may help to improve diagnosis and risk stratification in ICAD.
- Open Access
- 3 January 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (1) , 66
Proteomic Signaling of Dual-Specificity Phosphatase 4 (DUSP4) in Alzheimer’s Disease
DUSP4 is a member of the DUSP (dual-specificity phosphatase) subfamily that is selective to the mitogen-activated protein kinases (MAPK) and has been implicated in a range of biological processes and functions in Alzheimer’s disease (AD). In this study, we utilized the stereotactic delivery of adeno-associated virus (AAV)-DUSP4 to overexpress DUSP4 in the dorsal hippocampus of 5xFAD and wildtype (WT) mice, then used mass spectrometry (MS)-based proteomics along with the label-free quantification to profile the proteome and phosphoproteome in the hippocampus. We identified protein expression and phosphorylation patterns modulated in 5xFAD mice and examined the sex-specific impact of DUSP4 overexpression on the 5xFAD proteome/phosphoproteome. In 5xFAD mice, a substantial number of proteins were up- or down-regulated in both male and female mice in comparison to age and sex-matched WT mice, many of which are involved in AD-related biological processes, such as activated immune response or suppressed synaptic activities. Many proteins in pathways, such as immune response were found to be suppressed in response to DUSP4 overexpression in male 5xFAD mice. In contrast, such a shift was absent in female mice. For the phosphoproteome, we detected an array of phosphorylation sites regulated in 5xFAD compared to WT and modulated via DUSP4 overexpression in each sex. Interestingly, 5xFAD- and DUSP4-associated phosphorylation changes occurred in opposite directions. Strikingly, both the 5xFAD- and DUSP4-associated phosphorylation changes were found to be mostly in neurons and play key roles in neuronal processes and synaptic functions. Site-centric pathway analysis revealed that both the 5xFAD- and DUSP4-associated phosphorylation sites were enriched for a number of kinase sets in females but only a limited number of sets of kinases in male mice. Taken together, our results suggest that male and female 5xFAD mice responded to DUSP4 overexpression via shared and sex-specific molecular mechanisms, which might underly similar reductions in amyloid pathology in both sexes while learning deficits were reduced in only females with DUSP4 overexpression. Finally, we validated our findings with the sex-specific AD-associated proteomes in human cohorts and further developed DUSP4-centric proteomic network models and signaling maps for each sex.
- 3 January 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (1) , 66
Open AccessProteomic Signaling of Dual-Specificity Phosphatase 4 (DUSP4) in Alzheimer’s Disease
DUSP4 is a member of the DUSP (dual-specificity phosphatase) subfamily that is selective to the mitogen-activated protein kinases (MAPK) and has been implicated in a range of biological processes and functions in Alzheimer’s disease (AD). In this study, we utilized the stereotactic delivery of adeno-associated virus (AAV)-DUSP4 to overexpress DUSP4 in the dorsal hippocampus of 5xFAD and wildtype (WT) mice, then used mass spectrometry (MS)-based proteomics along with the label-free quantification to profile the proteome and phosphoproteome in the hippocampus. We identified protein expression and phosphorylation patterns modulated in 5xFAD mice and examined the sex-specific impact of DUSP4 overexpression on the 5xFAD proteome/phosphoproteome. In 5xFAD mice, a substantial number of proteins were up- or down-regulated in both male and female mice in comparison to age and sex-matched WT mice, many of which are involved in AD-related biological processes, such as activated immune response or suppressed synaptic activities. Many proteins in pathways, such as immune response were found to be suppressed in response to DUSP4 overexpression in male 5xFAD mice. In contrast, such a shift was absent in female mice. For the phosphoproteome, we detected an array of phosphorylation sites regulated in 5xFAD compared to WT and modulated via DUSP4 overexpression in each sex. Interestingly, 5xFAD- and DUSP4-associated phosphorylation changes occurred in opposite directions. Strikingly, both the 5xFAD- and DUSP4-associated phosphorylation changes were found to be mostly in neurons and play key roles in neuronal processes and synaptic functions. Site-centric pathway analysis revealed that both the 5xFAD- and DUSP4-associated phosphorylation sites were enriched for a number of kinase sets in females but only a limited number of sets of kinases in male mice. Taken together, our results suggest that male and female 5xFAD mice responded to DUSP4 overexpression via shared and sex-specific molecular mechanisms, which might underly similar reductions in amyloid pathology in both sexes while learning deficits were reduced in only females with DUSP4 overexpression. Finally, we validated our findings with the sex-specific AD-associated proteomes in human cohorts and further developed DUSP4-centric proteomic network models and signaling maps for each sex.
- 22 August 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (R1) , R54-R61
Non-coding RNAs in Alzheimer’s disease: perspectives from omics studies
Neurodegenerative diseases such as Alzheimer’s disease (AD) are characterized by the progressive loss of neurons in the brain and the spinal cord. The pathophysiology of AD is multifactorial with heterogeneous molecular manifestations. The lack of efficacious therapies for AD reinforces the importance of exploring in depth multifaceted disease mechanisms. Recent progresses on AD have generated a large amount of RNA-sequencing data at both bulk and single cell levels and revealed thousands of genes with expression changes in AD. However, the upstream regulators of such gene expression changes are largely unknown. Non-coding RNAs (ncRNAs) represent the majority of the human transcriptome, and regulatory ncRNAs have been found to play an important role in regulating gene expression. A single miRNA usually targets a number of mRNAs and thus such ncRNAs are particular important for understanding disease mechanisms and developing novel therapeutics. This review aims to summarize the recent findings on the roles of ncRNAs in AD from ncRNA-omics studies with a focus on ncRNA signatures, interactions between ncRNAs and mRNAs, and ncRNA-regulated pathways in AD. We also review the potential of specific ncRNAs to serve as biomarkers and therapeutic targets for AD. In the end, we point out future directions for studying ncRNAs in AD.
- 22 August 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (R1) , R54-R61
Non-coding RNAs in Alzheimer’s disease: perspectives from omics studies
Neurodegenerative diseases such as Alzheimer’s disease (AD) are characterized by the progressive loss of neurons in the brain and the spinal cord. The pathophysiology of AD is multifactorial with heterogeneous molecular manifestations. The lack of efficacious therapies for AD reinforces the importance of exploring in depth multifaceted disease mechanisms. Recent progresses on AD have generated a large amount of RNA-sequencing data at both bulk and single cell levels and revealed thousands of genes with expression changes in AD. However, the upstream regulators of such gene expression changes are largely unknown. Non-coding RNAs (ncRNAs) represent the majority of the human transcriptome, and regulatory ncRNAs have been found to play an important role in regulating gene expression. A single miRNA usually targets a number of mRNAs and thus such ncRNAs are particular important for understanding disease mechanisms and developing novel therapeutics. This review aims to summarize the recent findings on the roles of ncRNAs in AD from ncRNA-omics studies with a focus on ncRNA signatures, interactions between ncRNAs and mRNAs, and ncRNA-regulated pathways in AD. We also review the potential of specific ncRNAs to serve as biomarkers and therapeutic targets for AD. In the end, we point out future directions for studying ncRNAs in AD.
- Open Access
Molecular Networks and Key Regulators of the Dysregulated Neuronal System in Alzheimer’s Disease
SUMMARY: To study the molecular mechanisms driving the pathogenesis and identify novel therapeutic targets of late onset Alzheimer’s Disease (LOAD), we performed an integrative network analysis of whole-genome DNA and RNA sequencing profiling of four cortical areas, including the parahippocampal gyrus, across 364 donors spanning the full spectrum of LOAD-related cognitive and neuropathological disease severities. Our analyses revealed thousands of molecular changes and uncovered for the first-time multiple neuron specific gene subnetworks most dysregulated in LOAD. ATP6V1A , a critical subunit of vacuolar-type H + -ATPase (v-ATPase), was predicted to be a key regulator of one neuronal subnetwork and its role in disease-related processes was evaluated through CRISPR-based manipulation of human induced pluripotent stem cell derived neurons and RNAi-based knockdown in transgenic Drosophila models. This study advances our understanding of LOAD pathogenesis by providing the global landscape and detailed circuits of complex molecular interactions and regulations in several key brain regions affected by LOAD and the resulting network models provide a blueprint for developing next generation therapeutics against LOAD.
Open AccessMolecular Networks and Key Regulators of the Dysregulated Neuronal System in Alzheimer’s Disease
SUMMARY: To study the molecular mechanisms driving the pathogenesis and identify novel therapeutic targets of late onset Alzheimer’s Disease (LOAD), we performed an integrative network analysis of whole-genome DNA and RNA sequencing profiling of four cortical areas, including the parahippocampal gyrus, across 364 donors spanning the full spectrum of LOAD-related cognitive and neuropathological disease severities. Our analyses revealed thousands of molecular changes and uncovered for the first-time multiple neuron specific gene subnetworks most dysregulated in LOAD. ATP6V1A , a critical subunit of vacuolar-type H + -ATPase (v-ATPase), was predicted to be a key regulator of one neuronal subnetwork and its role in disease-related processes was evaluated through CRISPR-based manipulation of human induced pluripotent stem cell derived neurons and RNAi-based knockdown in transgenic Drosophila models. This study advances our understanding of LOAD pathogenesis by providing the global landscape and detailed circuits of complex molecular interactions and regulations in several key brain regions affected by LOAD and the resulting network models provide a blueprint for developing next generation therapeutics against LOAD.
- 1 July 1998
- Published by Wiley in Crop Science
- Vol. 38 (4) , 1076-1080
Molecular and Biochemical Characterization of a Non‐Robertsonian Wheat‐Rye Chromosome Translocation Line
- 1 July 1998
- Published by Wiley in Crop Science
- Vol. 38 (4) , 1076-1080
Molecular and Biochemical Characterization of a Non‐Robertsonian Wheat‐Rye Chromosome Translocation Line